How Ketamine Gets Into Your Bloodstream Through a Troche
When you place a ketamine troche under your tongue or between your cheek and gum, a carefully engineered biochemical process begins. Understanding this process helps explain why troches are an effective delivery method, why proper sublingual technique matters, and why simply swallowing the troche would dramatically reduce its effectiveness.
The Oral Mucosa: Your Body's Drug Delivery Highway
The inside of your mouth is lined with mucosal tissue — thin, highly vascularized epithelium through which small molecules can pass relatively easily. The sublingual mucosa (under the tongue) and buccal mucosa (inner cheek) are among the most permeable mucosal surfaces in the body, second only to nasal mucosa in terms of drug absorption rate.
Beneath this thin epithelial layer lies a dense network of capillaries and small veins that drain directly into the sublingual and facial veins, which empty into the superior vena cava and then the heart. Critically, this venous drainage bypasses the portal circulation — the system that carries blood from the gut to the liver before it reaches systemic circulation.
Why This Matters: First-Pass Avoidance
When you swallow a medication, it travels through the stomach and small intestine, is absorbed into the portal venous system, and passes through the liver before reaching the rest of the body. The liver metabolizes many drugs aggressively during this "first pass," reducing the amount of active drug that ultimately reaches the brain and other target tissues.
For ketamine specifically, oral bioavailability (when swallowed) is approximately 16 to 24 percent. The liver's cytochrome P450 enzymes — particularly CYP3A4 and CYP2B6 — convert a substantial portion of swallowed ketamine into norketamine and other metabolites before it has a chance to exert its intended effects.
Sublingual and buccal absorption largely sidestep this problem. Drug molecules absorbed through the oral mucosa enter systemic circulation directly, without first passing through the liver. This raises ketamine's bioavailability to approximately 20 to 30 percent — a meaningful improvement, though still substantially lower than IV administration's 100 percent bioavailability.
The Absorption Process Step by Step
Step 1: Dissolution
As the troche dissolves, it releases ketamine HCl into the saliva. The rate of dissolution depends on the troche base composition — PEG-based troches typically dissolve within 10 to 20 minutes. During this time, a drug-rich solution saturates the mucosa.
Step 2: Partitioning Into Mucosal Tissue
For a drug to cross the mucosal epithelium, it must partition from the aqueous saliva into the lipid-containing epithelial cell membranes. Ketamine is a moderately lipophilic molecule, meaning it can dissolve in both water and fat — a property that facilitates this membrane crossing. The unionized (free base) form of ketamine is more lipophilic and permeates membranes more readily than the ionized (protonated) form.
This is why salivary pH matters: at physiological pH of approximately 6.5 to 7.5 in the mouth, a portion of ketamine HCl exists in the unionized free base form, ready for membrane diffusion. If you rinse with acidic beverages before your session, you may slightly reduce absorption efficiency.
Step 3: Diffusion Through Epithelial Layers
Ketamine diffuses through the stratified squamous epithelium of the sublingual or buccal mucosa via transcellular pathways (through cells) and, to a lesser extent, paracellular pathways (between cells). The sublingual mucosa is relatively thin (100 to 200 micrometers) and non-keratinized, making it more permeable than buccal mucosa (500 to 600 micrometers, partially keratinized).
Step 4: Entry Into Capillary Blood
Once across the epithelium, ketamine enters the lamina propria — connective tissue rich in capillaries. The drug dissolves into blood plasma and is carried away from the absorption site. This continuous removal of drug from the tissue maintains a concentration gradient that drives further diffusion from the mucosal surface.
Step 5: Systemic Distribution
Ketamine is distributed rapidly throughout the body. It is highly lipophilic and crosses the blood-brain barrier efficiently. Peak plasma concentrations from sublingual or buccal administration typically occur within 15 to 45 minutes of the start of dissolution, though the time course varies with technique, individual physiology, and troche formulation.
Bioavailability: Why 20-30% Is Clinically Significant
At first glance, 20 to 30 percent bioavailability sounds low. But the clinical doses prescribed in troches account for this absorption fraction. A 200 mg troche, for example, delivers approximately 40 to 60 mg of ketamine to systemic circulation — a pharmacologically active amount capable of producing measurable antidepressant and dissociative effects.
Published pharmacokinetic studies of sublingual ketamine have found that doses in the range of 0.5 to 1.5 mg/kg produce plasma concentrations sufficient for therapeutic effect. A 70 kg patient receiving a 200 mg troche (with ~30% absorption) receives approximately 0.86 mg/kg in effective systemic dose — consistent with effective antidepressant ranges identified in research.
Factors That Influence Absorption Efficiency
Not every troche session produces identical drug levels. Several factors modulate how much ketamine actually gets absorbed:
- Retention time: Holding the dissolved troche in place for the full dissolution period (not spitting early) maximizes contact time with the mucosa.
- Swallowing saliva: Swallowing during dissolution carries drug-containing saliva to the stomach, where it undergoes first-pass metabolism. Most protocols advise patients to spit saliva or swallow minimally until after dissolution is complete.
- Mucosal blood flow: Exercise, vasoconstrictors (like certain cold medications), and even anxiety can reduce mucosal blood flow, slowing absorption.
- Food and drink: Eating before the session may alter oral pH and coat mucosal surfaces with food particles. Most protocols recommend fasting for 2 to 4 hours before a session.
- Individual variation: Differences in mucosal thickness, CYP enzyme activity, body weight, and sensitivity to ketamine all contribute to why one patient responds strongly to 150 mg while another needs 300 mg.
Sublingual vs. Buccal: Absorption Differences
The sublingual route (under the tongue) offers faster initial absorption due to thinner, non-keratinized epithelium and direct proximity to the sublingual vein. The buccal route (between cheek and gum) offers slower, more sustained absorption — and the choice between the two is worth considering carefully, as detailed in our sublingual vs. buccal comparison — sometimes preferred for patients who find rapid onset uncomfortable or disorienting.
Clinically, both routes provide comparable total drug exposure over a session, but the peak-to-trough profile differs. Some patients tolerate the buccal route better, especially early in treatment when managing the intensity of dissociative effects is a priority.
Key Takeaways
- Ketamine troches work by dissolving in the mouth and allowing ketamine to absorb through sublingual or buccal mucosa directly into blood vessels, bypassing the liver.
- Bioavailability is approximately 20 to 30 percent — higher than oral swallowing but lower than IV administration.
- First-pass avoidance is the primary pharmacokinetic advantage of troche delivery.
- Technique matters: holding the dissolved troche in place and minimizing saliva swallowing improves absorption.
- Individual factors including body weight, mucosal health, and enzyme activity cause variation in response between patients.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
- WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches
Share